1.报告期内，预计实现的营业收入与上年同期基本持平，主要系公司生物制品类产品增值税率由3%调 整至13%，对整体营收与盈利产生不利影响。2.报告期内，公司积极应对外部环境变化影响，加强技术 与产品研发，优化降本增效举措，提升经营效率，不断巩固公司科技创新实力与市场竞争力。同时，公 司保持市场投入强度，积极拓展创新业务与海外市场，销售费用同比有所增长，对当期经营结果有一定 不利影响。3.报告期内，公司基于实际情况与审慎性原则，计提了部分信用减值损失和资产减值损失， 亦对当期经营结果产生一定不利影响。 格隆汇1月29日丨诺唯赞(688105.SH)公布，预计公司2025年度实现归属于母公司所有者的净利润-2,000 万元至-1,000万元。 实现归属于母公司所有者的扣除非经常性损益的净利润-8,500万元至-7,000万元。 2025年度，公司预计出现亏损，主要原因如下： （原标题：诺唯赞(688105.SH)：2025年度预亏1000万元至2000万元） ...

格隆汇1月29日丨诺唯赞(688105.SH)公布，预计公司2025年度实现归属于母公司所有者的净利润-2,000 万元至-1,000万元。 实现归属于母公司所有者的扣除非经常性损益的净利润-8,500万元至-7,000万元。 2025年度，公司预计出现亏损，主要原因如下： 1.报告期内，预计实现的营业收入与上年同期基本持平，主要系公司生物制品类产品增值税率由3%调 整至13%，对整体营收与盈利产生不利影响。2.报告期内，公司积极应对外部环境变化影响，加强技术 与产品研发，优化降本增效举措，提升经营效率，不断巩固公司科技创新实力与市场竞争力。同时，公 司保持市场投入强度，积极拓展创新业务与海外市场，销售费用同比有所增长，对当期经营结果有一定 不利影响。3.报告期内，公司基于实际情况与审慎性原则，计提了部分信用减值损失和资产减值损失， 亦对当期经营结果产生一定不利影响。 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2026-002 南京诺唯赞生物科技股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经南京诺唯赞生物科技股份有限公司（以下简称"公司"）财务部门初步测 算，预计公司2025年度： 1. 实现归属于母公司所有者的净利润-2,000万元至-1,000万元。 2. 实现归属于母公司所有者的扣除非经常性损益的净利润-8,500万元至 -7,000万元。 （三）本次业绩预告相关财务数据未经注册会计师审计。 三、本期业绩变化的主要原因 2025年度，公司预计出现亏损，主要原因如下： 1.报告期内，预计实现的营业收入与上年同期基本持平，主要系公司生物制 品类产品增值税率由3%调整至13%，对整体营收与盈利产生不利影响。 2.报告期内，公司积极应对外部环境变化影响，加强技术与产品研发，优化 降本增效举措，提升经营效率，不断巩固公司科技创新实力与 ...

南财智讯1月29日电，诺唯赞发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为-2000 万元至-1000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为-8500万元 至-7000万元。2025年度，公司预计出现亏损，主要原因如下：报告期内，预计实现的营业收入与上年 同期基本持平，主要系公司生物制品类产品增值税率由3%调整至13%，对整体营收与盈利产生不利影 响；报告期内，公司积极应对外部环境变化影响，加强技术与产品研发，优化降本增效举措，提升经营 效率，不断巩固公司科技创新实力与市场竞争力。同时，公司保持市场投入强度，积极拓展创新业务与 海外市场，销售费用同比有所增长，对当期经营结果有一定不利影响；报告期内，公司基于实际情况与 审慎性原则，计提了部分信用减值损失和资产减值损失，亦对当期经营结果产生一定不利影响。 ...

Group 1 - The core business of the company includes research and development of functional proteins and high molecular organic materials, with a focus on biological reagents, in vitro diagnostics, and antibody drug development [2] - As of September 30, the company reported a total revenue of 952 million yuan for the period from January to September 2025, representing a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.6152 million yuan, down 63.57% year-on-year [2] - The company has a total of 9,447 shareholders, which is an increase of 9.90% compared to the previous period, while the average circulating shares per person decreased by 9.01% to 42,101 shares [2] Group 2 - The company has distributed a total of 731 million yuan in dividends since its A-share listing, with 611 million yuan distributed over the past three years [3] Group 3 - On January 22, the company's stock price increased by 0.70%, with a trading volume of 35.0056 million yuan [1] - The financing buy-in amount on January 22 was 1.6545 million yuan, while the financing repayment was 3.3677 million yuan, resulting in a net financing buy-in of -1.7132 million yuan [1] - The total balance of margin trading for the company as of January 22 was 123 million yuan, accounting for 1.43% of the circulating market value, which is above the 90th percentile level over the past year [1]

Core Viewpoint - The Nanjing Municipal Market Supervision Administration is enhancing the intellectual property protection capabilities of local medical device companies to support their international market expansion and innovation development [1][3]. Group 1: Training and Participation - A second phase of practical training on intellectual property protection for medical device companies was organized, involving over 20 representatives from listed and key export companies, as well as personnel from intellectual property law firms and service agencies [1]. - The training included site visits to key export companies, such as Nanjing Shuangwei Biomedical Technology Co., Ltd. and Nanwei Medical Technology Co., Ltd., which have established significant international presence and innovation capabilities [1]. Group 2: Expert Insights - Experts provided insights on overseas trademark brand strategy and patent risk prevention for medical device companies, discussing strategies and methods for foreign intellectual property protection [2]. - The training covered a five-step strategy for brand building and addressed risks associated with overseas trademark layout, as well as typical cases of patent disputes in the medical device sector [2]. Group 3: Future Initiatives - The Nanjing Municipal Market Supervision Administration plans to continue optimizing training formats and content to align with the development trends of the medical device industry and the needs of companies, thereby supporting innovation and internationalization [3].

证券代码：688105 证券简称：诺唯赞 公告编号：2026-001 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 6 月 | 年 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 12.77万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.03% | | | | | | | ...

诺唯赞公告称，公司于2025年6月19日通过回购股份议案，预计用500万元 - 1000万元自有资金，以不超 30元/股的价格回购股份，用于员工持股计划或股权激励，回购期限至2026年6月18日。截至2025年12月 31日，公司累计回购12.77万股，占总股本的0.03%，累计已回购金额299.97万元，实际回购价格区间为 23.06元/股 - 24.36元/股。 ...

Core Insights - The GLP-1 sector is experiencing significant growth potential, and the company is leveraging its upstream raw material supply advantages to explore the GLP-1 peptide raw material market [2] - The company has successfully provided hundreds of kilograms of supply to multiple domestic clients during the 2024 reporting period, complying with GMP standards [2] - The company is focused on enhancing its product and service advantages across the GLP-1 fermentation recombinant method value chain, addressing client needs for product quality, cost, and capacity [2] Business Operations - The company has engaged in compliance submissions and audits with several clients, ensuring adherence to regulatory standards [2] - Ongoing efforts include advancing the DMF filing for core enzyme raw materials and intermediates to support clients' compliance submissions [2] - The business faces uncertainties in future performance due to market competition, supply-demand changes, technological iterations, and geopolitical factors [2]

Group 1 - The core viewpoint of the article is that the company, 诺唯赞, has confirmed it is not planning any changes to its controlling rights as of now [1] Group 2 - The company responded to investor inquiries on its interactive platform regarding the status of its controlling rights [1]